Clinical trials: Chronic Myeloid Leukemia, open to volunteers
Chronic Myeloid Leukemia, Chronic Phase
Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase
The goal of this retrospective observational study is to evaluate any possible association between plasma concentrations of ponatinib and its pharmacodynamics (efficacy/tolerability) in patients affected by chronic myeloid…
- Trial name
- PHOENICS (NCT06119269)
- Testing
- Therapeutic drug monitoring, Molecular Response
- Where
- 5 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Pisa
Chronic Myeloid Leukemia
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
This is a prospective multi-center study to investigate efficacy and safety of the third generation tyrosine kinase inhibitors (TKIs) combined with azacitidine and B-cell lymphoma-2 (Bcl-2) inhibitor in patients with myeloid…
- Trial name
- NCT06390306
- Testing
- Ponatinib, Azacitidine, Venetoclax
- Where
- 15 sites in China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
The goal of this clinical trial is to test the ability to restore gut microbiota to healthier levels in patients with blood cancers scheduled to have stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- MAST (NCT06355583)
- Testing
- EBX-102
- Where
- 8 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Imperial College London
Hematologic Malignancy, GvHD
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell…
- Conditions
- Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic
- Trial name
- NCT06462365
- Testing
- TRX103
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tr1X, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Efficacy and Safety of Selinexor Combined with Azacitidine as Maintenance Therapy in High-Risk Myeloid Neoplasms Patients Post-Transplantation: A Single-Center, Single-Arm, Exploratory Study
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
- Trial name
- NCT06900088
- Testing
- Selinexor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Myeloid Leukemia
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
The purpose of this study is to evaluate Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
- Trial name
- CARCML (NCT05282108)
- Testing
- Carcemia, Glivec
- Where
- 4 sites in Egypt
- Volunteers
- 240 people
- Sponsor
- Hikma Pharmaceuticals LLC
Chronic Myeloid Leukemia (CML)
Evaluation of CD47, "Do Not Eat Me" Signal Expression in Chronic Myeloid Leukemia
Chronic myeloid leukemia is a myeloid neoplasm characterized by the overproduction of mature granulocytes . Cluster of differentiation 47 (CD47) is a membrane protein, which is over-expressed by virtually all cancers and…
- Trial name
- NCT06865443
- Volunteers
- 50 people
- Sponsor
- Assiut University
Chronic Myeloid Leukemia, Accelerated Phase CML
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI)…
- Trial name
- NCT06453902
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Leukemia,Myeloid, Chronic
Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML
Gut microbiome (GM) is acquiring increasing importance in human health and disease. GM influences hematopoiesis and immune cells types differentiation. Patients with cancer are characterized by dysbiosis and compromised immunity.
- Trial name
- MICROBIO-LMC (NCT06724536)
- Testing
- non interventional study with the use of biological samples.
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Carmen Fava
Chronic Myeloid Leukemia (CML)
Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial
Imatinib is a tyrosine kinase inhibitor that has improved the prognosis of patients with chronic myeloid leukemia (CML). CML has become a chronic disease requiring long-term administration of imatinib.
- Trial name
- K2SPIRIT (NCT06646978)
- Testing
- Imatinib (STI571)
- Where
- France
- Volunteers
- 787 people
- Sponsor
- Poitiers University Hospital
Leukemia,Myeloid, Chronic
Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy
French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological…
- Trial name
- BIO-TIMER (NCT06130787)
- Testing
- Blood and bone marrow sample
- Where
- 17 sites in France
- Volunteers
- 321 people
- Sponsor
- University Hospital, Clermont-Ferrand
Primary Myelofibrosis, Polycythemia Vera
Myeloproliferative Neoplasms (MPNs) Patient Registry
The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.
- Conditions
- Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Mastocytosis
- Trial name
- NCT02760238
- Testing
- Observational
- Where
- Canada
- Volunteers
- 5,000 people
- Sponsor
- University Health Network, Toronto
Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
This is a single-center randomized open-label phase II clinical trial to compare relapse prophylaxis with sorafenib and observation after graft-versus-host disease prophylaxis with post-transplantation bendamustine and…
- Conditions
- Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Myeloproliferative Neoplasm
- Trial name
- SoraGVL (NCT06532084)
- Testing
- Sorafenib
- Where
- Russia
- Volunteers
- 88 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Vitamin A and D Supplementation in Allogeneic HCT
The therapy under investigation is the addition of 300 000 IU of vitamin A and 100 000 IU of vitamin D before conditioning. The study will include patients with malignant diseases in hematologic response with indications for…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma
- Trial name
- VitaStem (NCT06508099)
- Testing
- Vitamin A, Vitamin D3
- Where
- Russia
- Volunteers
- 220 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Chronic Myelogenous Leukemia, CML Chronic Phase
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)
HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation.
- Conditions
- Chronic Myelogenous Leukemia, CML Chronic Phase, CML Accelerated Phase
- Trial name
- NCT06530810
- Testing
- HS-10382+Flumatinib
- Volunteers
- 100 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Neoplasm
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
This study is a multicenter, single-arm, prospective phase II clinical trial that evaluates the efficacy and safety of an intensive conditioning regimen with thiotepa combined with busulfan, fludarabine, and cytarabine for…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, Myeloid Sarcoma
- Trial name
- NCT06111612
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Chronic Myeloid Leukemia, BCR/ABL-Positive
Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission
In recent years, the goal of stopping drug therapy, also known as treatment-free remission (TFR), is emerging as one of the management goals of chronic myeloid leukemia (CML) therapy.
- Trial name
- NCT05439889
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Combining Active and Passive DNA Hypomethylation
This is a multicentre, randomized, parallel-group, placebo-controlled, double-blind phase 2 study of the efficacy and safety of oral vitamin C supplement in combination with azacitidine in patients with higher-risk MDS, CMML-2 or…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- EVI-3 (NCT03999723)
- Testing
- Vitamin C
- Where
- 10 sites in Denmark, Sweden
- Volunteers
- 196 people
- Sponsor
- Kirsten Grønbæk
Chronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Real-Life Database
Establish the largest possible real-life cohort collecting long-term follow-up of a maximum number of CML patients in order to carry out observational studies: epidemiological, identification of subgroups according to their…
- Trial name
- NCT05963061
- Where
- 14 sites in France
- Volunteers
- 3,500 people
- Sponsor
- University Hospital, Clermont-Ferrand
Chronic Myeloid Leukemia in Remission
Chronic Kidney Disease Patient in Chronic Myloied Leukemia
To study the Prevalence ,Characteristics and outcome of CKD in patiants with chronic myeloid leukemia .
- Trial name
- NCT06266975
- Testing
- Biobsy from kidney
- Volunteers
- 40 people
- Sponsor
- Sahar Mohammed Gad